Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Asunaprevir

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Epclusa's fast-tracked Chinese approval might be late for Gilead
    Epclusa's fast-tracked Chinese approval might be late for Gilead

    31 May 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded

    Angus Liu FIERCE PHARMA
    31 May 2018
    Share Share
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

    06 Jan 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report

    Angus Liu FIERCE PHARMA
    06 Jan 2018
    Share Share
    Bristol-Myers Squibb receives CFDA approval for all-oral regimen for HCV Daklinza in combo with Sunvepra
    Bristol-Myers Squibb receives CFDA approval for all-oral regimen for HCV Daklinza in combo with Sunvepra

    02 May 2017

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=101696&sid=2

    PHARMABIZ
    02 May 2017
    Share Share
    Recent Success in HCV Treatment Brings Relief to Patients
    Recent Success in HCV Treatment Brings Relief to Patients

    07 Nov 2016

    // DRUG DEVELOPMENT

    http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx

    DRUG DEVELOPMENT
    07 Nov 2016
    Share Share
    Japan's PMDA reviews hep B risk link to hep C therapies
    Japan's PMDA reviews hep B risk link to hep C therapies

    04 May 2016

    // EJ Lane FIERCE ASIA

    http://www.fiercepharma.com/pharma-asia/japan-s-pmda-reviews-hep-b-risk-link-to-hep-c-therapies

    EJ Lane FIERCE ASIA
    04 May 2016
    Share Share
    BMS PhIII hep C combo results a milestone for China plans
    BMS PhIII hep C combo results a milestone for China plans

    22 Feb 2016

    // EJ Lane FIERCE PHARMA ASIA

    http://www.fiercepharmaasia.com/story/bms-phiii-hep-c-combo-results-milestone-china-plans/2016-02-22

    EJ Lane FIERCE PHARMA ASIA
    22 Feb 2016
    Share Share